Dysmenorrhea – Pipeline Review, H1 2012

Published : February 2012
No. of Pages : 59

Price:

Dysmenorrhea – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Dysmenorrhea - Pipeline Review, H1 2012', provides an overview of the Dysmenorrhea therapeutic pipeline. This report provides information on the therapeutic development for Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dysmenorrhea. 'Dysmenorrhea - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dysmenorrhea.
- A review of the Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dysmenorrhea pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dysmenorrhea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dysmenorrhea pipeline depth and focus of Dysmenorrhea therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Dysmenorrhea Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Dysmenorrhea 8
Dysmenorrhea Therapeutics under Development by Companies 10
Dysmenorrhea Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Dysmenorrhea Therapeutics – Products under Development by Companies 17
Dysmenorrhea Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Dysmenorrhea Therapeutics Development 19
Columbia Laboratories Inc. 19
Plethora Solutions Holdings plc 20
China Aoxing Pharmaceutical Co., Inc 21
PDC Biotech GmbH 22
Nobelpharma Co., Ltd. 23
Vantia Therapeutics 24
Jiangsu Kanion Pharmaceutical Co., Ltd. 25
Dysmenorrhea – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Peptidometics - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PDC41 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PDC31 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Lidocaine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PSD508 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
VA111913 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Viagra - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Gestodene + Ethinyl Estradiol - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Fenellin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vitagnus - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Kanion - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TJSL Capsule - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NPC-01 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Mefenamic Acid - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Colpermin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Zinc - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Omega-3 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
T109 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dysmenorrhea Therapeutics – Discontinued Products 50
Dysmenorrhea Therapeutics - Dormant Products 51
Dysmenorrhea – Product Development Milestones 52
Featured News & Press Releases 52
Jul 19, 2010: Aoxing Pharma Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules 52
Jul 19, 2010: Aoxing Pharmaceutical Company Reports Enrollment Progress On Phase III Clinical Trial Of TJSL Capsules 52
Mar 26, 2010: Vantia Therapeutics Reveals Structure Of Its Novel Small Molecule Treatment For Dysmenorrhoea, VA111913 53
Jan 05, 2010: China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug 53
Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007 54
Nov 09, 2007: Merck Agreement to Resolve U.S. VIOXX Product Liability Lawsuits 55
Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007. 55
Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007 55
Apr 30, 2007: Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014 56
Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007. 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 59
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Dysmenorrhea, H1 2012 8
Products under Development for Dysmenorrhea – Comparative Analysis, H1 2012 9
Number of Products under Development by Companies, H1 2012 11
Number of Products under Investigation by Universities/Institutes, H1 2012 12
Comparative Analysis by Late Stage Development, H1 2012 13
Comparative Analysis by Mid Clinical Stage Development, H1 2012 14
Comparative Analysis by Early Clinical Stage Development, H1 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 16
Products under Development by Companies, H1 2012 17
Products under Investigation by Universities/Institutes, H1 2012 18
Columbia Laboratories Inc., H1 2012 19
Plethora Solutions Holdings plc, H1 2012 20
China Aoxing Pharmaceutical Co., Inc, H1 2012 21
PDC Biotech GmbH, H1 2012 22
Nobelpharma Co., Ltd., H1 2012 23
Vantia Therapeutics, H1 2012 24
Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2012 25
Assessment by Monotherapy Products, H1 2012 26
Assessment by Combination Products, H1 2012 27
Assessment by Stage and Route of Administration, H1 2012 29
Assessment by Stage and Molecule Type, H1 2012 31
Dysmenorrhea Therapeutics – Discontinued Products 50
Dysmenorrhea Therapeutics – Dormant Products 51

List of Figures
Number of Products under Development for Dysmenorrhea, H1 2012 8
Products under Development for Dysmenorrhea – Comparative Analysis, H1 2012 9
Products under Development by Companies, H1 2012 10
Products under Investigation by Universities/Institutes, H1 2012 12
Late Stage Products, H1 2012 13
Mid Clinical Stage Products, H1 2012 14
Early Clinical Stage Products, H1 2012 15
Pre-Clinical Stage Products, H1 2012 16
Assessment by Monotherapy Products, H1 2012 26
Assessment by Combination Products, H1 2012 27
Assessment by Route of Administration, H1 2012 28
Assessment by Stage and Route of Administration, H1 2012 29
Assessment by Molecule Type, H1 2012 30
Assessment by Stage and Molecule Type, H1 2012 31

Dysmenorrhea – Pipeline Review, H1 2012

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: